Kmall, tried to post this on YMB but could not, why am I not surprised…

[biopearl123]

Exactly, not B. Riley which will just review what we already know. Appropriate meetings would be AACR, ASCO, EHA and of course ASH. I don’t think too much new will happen until any of these. News of oral prep probably reserved for more research oriented meetings (e.g.AACR). Anyway as far as subgroup analysis, we already know a lot, high transfusion burden patients, high EPO patients, genetic subtypes, RS + and RS-. The 1 year TI rates take a while to “mature” (look how long it took for the Part I patients to be presented at ASH this year) but we will certainly see them “in a future medical meeting. If a patient has high intrinsic EPO already, giving them parenteral EPO is not likely to help (take note luspatercept patients in the COMMANDS study. Little doubt luspatercept will be better than EPO but little doubt Imetelstat is and will be better than luspatercept in both high and low EPO patients. Since we discussed this here I won’t post it on chat. Regards, bp